Day 1 - Friday, 6 September - Pre-conference Education Course
Topics
Meeting category
Date(s)
6 Sep 2019 - 8 Sep 2019
Location
Cairo,
Egypt
Organizer
Platinum Level Support
Sponsor logos
Conference on Liver Disease in Africa (COLDA) 2019
Related Enduring Materials
Enduring Materials
Downloads:
Opening Session - 09:30
John Ward, MD
09:30 EET
Parallel sessions - Integrated training on:
Basic colonoscopy
Manar Salah, Ain Shams University, Egypt
Basic upper endoscopy
Ahmed Talaat Elganzory, Ain Shams University, Egypt
Point of care testing
Elena Ivanova Reipold, FIND, Switzerland; Cynthia Tamandjou, University of Cape Town, South Africa; Shivraj Bhoite, Molbio Diagnostics, India; Marc Amphlett, Genedrive, United Kingdom
14:00 EET
Opening of the conference
Session Chair: Manal El-Sayed, MD, PhD
Ain Shams University, Cairo, Egypt
14:15 EET
Keynote lecture: Global efforts on viral hepatitis elimination
Coalition for Global Hepatitis Elimination, Task Force for Global Health / Rollins School of Public Health, Emory University, United States
15:15 EET
Viral hepatitis and pregnancy
15:45 EET
Discussion
Session 1: HCC and its management -
Chair
Olufunmilayo Lesi, FWACP, FMCP
WHO Regional Office for Africa, Congo
16:30 EET
Epidemiology, burden of disease and outcomes of HCC in Africa
16:55 EET
Improving risk stratification and early detection of HCC in Africa
17:20 EET
Surgical therapy for HCC – including resection and liver transplantation
18:35 EET
Needs for research and advocacy for HCC in Africa
Discussion
Day 2 - Saturday, 7 September
- 08:00
08:00 EET
Industry Supported Symposium I - Gilead: SOF/VEL/VOX. Current position in HCV management in today’s guidelines
Session 2: Management of viral hepatitis (I) - HBV related -
Chair
Wendy Spearman, MD, PhD
University of Cape Town, South Africa
Thomas Berg, MD
University Hospital Leipzig, Germany
09:00 EET
Simplification of HBV treatment algorithm
Ayman Yosry, MD
Cairo University, Egypt
09:25 EET
Treatment of HBV in sub-Saharan Africa
Abstract-driven presentations
09:50 EET
Prevalence of Hepatitis B Surface Antigen (HBsAg) positivity and its associated factors in Rwanda/risk factors for viral hepatitis C infection in Rwanda: results from a nationwide screening program #01-A/#01-B
Jean Damascene Makuza
#01-A /#01- B
10:00 EET
Prenatal consultation as a starting point for family screening of hepatitis B virus, the CI cohort ANRS 12359 #02
Nanelin Alice Guingane
#02
10:10 EET
Analysis of the National Hepatitis B Viral Load Testing Programme in Uganda #03
Viola Kasone
#03
10:20 EET
High rates of HBV functional cure among HIV/HBV-coinfected patients on ART in Zambia #04
Michael Vinikoor
#04
Session 3: Management of viral hepatitis (II) - HCV related -
Chair
Mark Nelson, MD, FRCP
Chelsea and Westminster Hospital, United Kingdom
Chair: Mary Afihene, MBChB, FWACP
Kwame Nkrumah University, Ghana
Abstract-driven presentations
11:50 EET
Hepatitis C treatment among people who inject drugs in Kenya: preliminary findings of the test and link to care for injecting drug users study C infection in Rwanda: results from a nationwide screening program #05
Mercy Nyakowa
#05
12:00 EET
Efficacy of Direct-Acting Antiviral (DAA) regimens in HIV/HCV-coinfected patients in Libya #06
Nagat Bousifi
#06
12:10 EET
Assessment of liver fibrosis after Direct-Acting Antiviral therapy in compensated and decompensated HCV-related liver diseases #07
Mohammed Mohammed
#07
12:20 EET
Heading toward hepatitis C virus elimination: Tunisian experience, achievements and prospects #08
Mouna Safer
#08
13:15 EET
Get your paper published in The Lancet
Robert Brierley
The Lancet Gastroenterology & Hepatology, United Kingdom
Session 4: Public health - Egypt’s model of care -
Chair
Gamal Esmat, MD
Cairo University, Egypt
John Ward, MD
Centers for Disease Control, USA
14:45 EET
Screening of 50 million people
Manal Ey-Sayed, MD, PhD
Ain Shams University, Egypt
15:05 EET
Scaling up treatment
Wahid Doss, MD
Cairo University, Egypt
15:25 EET
Round Table discussion: Translation of Egypt’s experience to the rest of Africa
Wahid Doss, MD
Cairo University, Egypt
Gamal Esmat, MD
Cairo University, Egypt
Magdy El-Serafy, MD
Cairo University, Egypt
Imam Waked, MB, BCh, MSc, MD, FAASLD
National Liver Institute, Egypt
Mohamed Hassany, MD
National Hepatology and Tropical Medicine Research Institute, Egypt
Jean Damascene Makuza, MD
Rwanda Biomedical Center, Rwanda
Session 5: Civil society contribution in Africa - organized by World Hepatitis Alliance -
Chair
Cary James
World Hepatitis Alliance, United Kingdom
Gamal Shiha, MD, MBBH, MSc
Mansoura University Hospitals ,Egypt
16:40 EET
Round table Discussion: the role of patient support groups
Cary James
World Hepatitis Alliance, United Kingdom
Bisi Bright
LiveWell Initiative LWI, Nigeria
Mohamed El-Wahsh
Tanya Masr, Egypt
Ammal Metwally, MD, PhD
National Research Center, Egypt
Coulibaly Alioune Badara, MD
Association pour la Promotion de la Sante et le Developpement (APSAD), Mali
Kenneth Kabagambe, BA
The National Organisation for People Living with Hepatitis B (NOPLHB), Uganda
Elodie Sanasee
Prévention Information et Lutte contre le SIDA (PILS), Mauritius
Day 3 - Sunday 8 September
Industry Supported Symposium II - 08:00
08:00 EET
Economic impact and funding for hepatitis elimination - drawing from Egypt’s success
Session 6: NASH/NAFLD management in Africa -
Chair
John Rwegasha, MBChB, M.MED, FRCP, MSc
Muhimbili National Hospital, Tanzania
Imam Waked, MB, BCh, MSc, MD, FAASLD
National Liver Institute, Egypt
Abstract - driven presentations
10:00 EET
HCC developed following DAAs treatment does not display more aggressive pattern #09
Gamal Shiha
#09
10:10 EET
Factors associated with liver toxicity among HIV infected children and adolescents attending a national referral pediatric HIV clinic in Uganda #10
Bonny Mulindwa
#10
10:20 EET
Prevalence of fatty liver disease and associated factors among outpatients attending internal medicine clinics at Muhimbili University of Health and Allied Sciences Academic Medical Centre, Tanzania #11
Nontobeko Simelane
#11
10:30 EET
Best of Posters
Chair: Mark Nelson, MD, FRCP
Chelsea and Westminster Hospital, United Kingdom
Manal El-Sayed, MD, PhD
Ain Shams University, Cairo, Egypt
11:30 EET
Industry Supported Symposium III - Pharco: Innovation of access to treatment: Real Life Scenarios
Session 7: WHO sponsored session on viral hepatitis and universal health coverage - 14:00
14:30 EET
Innovative financing and financial protection: inclusion of viral hepatitis services
Awad Mataria, PhD
WHO/EMRO, Egypt
14:45 EET
Discussion
Closure of the conference - 15:30
15:30 EET
Conference Summary and Conclusions from the Conference Co-Chairs
15:50 EET
President of Ain Shams University speech
16:00 EET
Minister of Health speech
Her Excellency Dr. Hala Zayed
Ministry of Health, Egypt
16:10 EET
Minister of Investment and International Cooperation speech
Her Excellency Dr. Sahar Nasr
Ministry of Investment and International Coorperation, Egypt
16:20 EET
Minister of Higher Education speech
His Excellency Prof. Khaled Abdel-Ghaffar
Ministry of Higher Education, Egypt
Overview
Welcome
The very successful Conference on Liver Disease in Africa took place on 6 - 8 September 2019 in Cairo, Egypt.
The Conference Organizers would like to give a special thank you to all the invited speakers and participants for their valued contribution to this meeting!
Additionally, we would like to thank Pharco Pharmaceuticals, Abbott Laboratories, Gilead Sciences, Mylan, Sysmex and Cepheid for making this Conference possible.
Meeting materials such as presentations, videos and event photos are available on this website, given that the speakers have provided their permission. The Abstract Book and digital versions of the posters can also be downloaded here.
Please feel free to subscribe to our newsletter to stay up to date.
Program Chairs 2019
General Information
Meeting Objectives
COLDA aims to:
- Gather experts from the African region involved in the research, diagnosis, and treatment of liver diseases in an interactive conference setting
- Discuss the diagnostic, therapeutic and preventative efforts of liver disease tailored to regional and local needs, translating best practices into daily practice guidelines and policies
- Contribute towards hepatitis elimination efforts
- Leverage on the findings from international studies through the delivery of updates from major meetings that can be applied at the local and regional level to combat liver diseases
- Facilitate a robust dialogue among participants through interactive networking and a networking reception
- Foster new and lasting interdisciplinary partnerships and collaborations among various researchers to improve knowledge sharing with aim of combating liver diseases in Africa
- Gather experts from the African region involved in the research, diagnosis, and treatment of liver diseases in an interactive conference setting
- Discuss the diagnostic, therapeutic and preventative efforts of liver disease tailored to regional and local needs, translating best practices into daily practice guidelines and policies
- Contribute towards hepatitis elimination efforts
- Leverage on the findings from international studies through the delivery of updates from major meetings that can be applied at the local and regional level to combat liver diseases
- Facilitate a robust dialogue among participants through interactive networking and a networking reception
- Foster new and lasting interdisciplinary partnerships and collaborations among various researchers to improve knowledge sharing with aim of combating liver diseases in Africa
Learning Objectives
After participating in COLDA, participants will be able to:
- Discuss the epidemiology and treatment of liver disease at an individual and population level
- Ensure the knowledge and availability of HBV and HCV therapy and their correct usage
- Discuss evolving modalities of monitoring liver disease and their availability in the African setting
- Update on new developments in the investigation of liver disease and their use in an African setting
- Discuss the epidemiology and treatment of liver disease at an individual and population level
- Ensure the knowledge and availability of HBV and HCV therapy and their correct usage
- Discuss evolving modalities of monitoring liver disease and their availability in the African setting
- Update on new developments in the investigation of liver disease and their use in an African setting
Practical Information
Certificate of Attendance
A certificate of attendance was sent per e-mail after the meeting.
Language
The official conference language was English.
Disclaimer
This conference is intended for educational purposes only and aims to offer participants the opportunity to share information. The organizing secretariat of this conference, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this conference. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the conference.
Liability and Insurance
By registering for the conference participants agree that the organizers do not accept responsibility for any applicable insurances. Participants are advised to take out their own insurance policies.
Committees
Organizing Committee
Papa Saliou Mbaye
MD
Charles Boucher
MD, PhD
Manal El-Sayed
MD, PhD
Mark Nelson
MD
Kosh Agarwal
MD
Olufunmilayo Lesi
FWACP, FMCP
Scientific Committee
To augment the organizing committee, the following are scientific committee
members
- Mary Afihene, MBChB, FWACP – Kwame Nkrumah University, Ghana
- Geoffrey Dusheiko, MBBCh, FCP, FRCP - Kings College Hospital, UK
- Alice Guingané, MD, MPH - Hospitalier Universitaire Yalgado Ouedraogo, Burkina Faso
- Emmanuel Musabeyezu, MD, FCP – King Faisal Hospital, Rwanda
- Gibril Ndow, MD – Imperial College London, Gambia
- John Rwegasha, MBChB, M.MED, FRCP, MSc - Muhimbili National Hospital, Tanzania
- Edford Sinkala, MD, PhD - University Teaching Hospital / University of Zambia, Zambia
- Sonjelle Shilton, MPH - Foundation for Innovative New Diagnostics (FIND), Switzerland
- Christian Tzeuton, MD – Douala Medical School / Société Camerounaise de Gastro-Enterologie, Cameroon
Support
Platinum Level
Gold Level
Bronze Level
Endorsers
Meeting Partners and Endorsers
Media
Image
Language
Related Programs
Sorry… This form is closed to new submissions.